Stay updated with breaking news from Astrazeneca Evusheld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
Detailed results from the PROVENT Phase III pre-exposure prophylaxis trial showed that AstraZeneca’s Evusheld, formerly AZD7442, reduced the risk of...
Quebec health officials apologize after tweeting link to porn site instead of government COVID update.
Scoop Community provides New Zealand Community news and views
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the...